Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 9 Issue 7

Intraepidermal Histiocytes as a Histologic Marker of Cutaneous Drug Rash

Bronagh Mc Gee1* and Paul Hartel2,3

1University of Galway, School of Biological and Chemical Sciences, Ireland
2Sligo University Hospital, Department of Pathology, Ireland
3West Virginia University School of Medicine, USA

*Corresponding Author: Bronagh Mc Gee, University of Galway, School of Biological and Chemical Sciences, Ireland.

Received: June 15, 2025; Published: June 30, 2025

Abstract

To evaluate the presence of intraepidermal histiocytes in drug reactions, we reviewed 20 cases of clinical drug rash and their histologic features. Rashes identified as drug-induced by a team of dermatologists were biopsied. Histologically, the prevalence of intraepidermal histiocytes were quantified using S-100 immunohistochemistry and compared with normal skin sections. We found that the prevalence of intraepidermal histiocytes in drug reactions is twice that of normal skin, as well as a small comparative sample of non-drug induced rashes. S-100 positive intraepidermal histiocytes may be a specific histologic and diagnostic marker for drug-induced rash.

 Keywords: Cutaneous Drug Rash; Drug Eruption; Langerhans Cells; S-100

References

  1. Ernst M., et al. “Histopathologic Features of Maculopapular Drug Eruption”. Dermatopathology2 (2022): 111-121.
  2. Pascucci A. “Granulomatous drug eruption associated with imipramine”. JAAD Case Reports2 (2018): 152-154.
  3. Sehgal V., et al. “Lichenoid tissue reaction/interface dermatitis: Recognition, classification, etiology, and clinicopathological overtones”. Indian Journal of Dermatology, Venereology, and Leprology4 (2011): 418.
  4. , et al. “CD1a+ Langerhans cells in the peritumoral epidermis of basal cell carcinoma”. Actas Dermo-Sifiliograficas 100.8 (2009): 700-705.
  5. , et al. “Immunohistochemical analysis of S100-positive epidermal Langerhans cells in dermatofibroma”. Anais Brasileiros de Dermatologia 95.5 (2020): 627-630.
  6. Fernandez-Flores A., et al. “Congenital cutaneous lymphadenoma”. Journal of Cutaneous Pathology11 (2017): 954-957.
  7. Al Aboud., et al. “Cutaneous Adverse Drug Reaction (CADR)”. (2020).
  8. Baroni, A., et al “Lyell’s Syndrome”. SKINmed: Dermatology for the Clinician 4.4 (2005): 221-225.
  9. , et al. “Langerhans’ cell distribution in drug eruption”. Acta dermato-venereologica 72.3 (1992): 175-177.
  10. Del Pozzo‐Magaña BR., et al. “Drugs and the skin: A concise review of cutaneous adverse drug reactions”. British Journal of Clinical Pharmacology (2022).
  11. Ramdial PK., et al. “Drug-induced cutaneous pathology”. Journal of Clinical Pathology6 (2009): 493-504.
  12. Tiwari, P., et al. “Toxic epidermal necrolysis: an update”. Asian Pacific Journal of Tropical Disease2 (2013): 85-92.
  13. Williams O., et al. “Granuloma”. PubMed. (2022).

Citation

Citation: Bronagh Mc Gee and Paul Hartel. “Intraepidermal Histiocytes as a Histologic Marker of Cutaneous Drug Rash”.Acta Scientific Medical Sciences 9.7 (2025): 132-135.

Copyright

Copyright: © 2025 Bronagh Mc Gee and Paul Hartel. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





Contact US